{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:29:47Z","timestamp":1764883787556,"version":"3.46.0"},"reference-count":35,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013329","name":"National Sanitarium Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,20]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Tuberculosis (TB) is a major global cause of morbidity and mortality. Emerging evidence in high-burden settings suggests significant long-term sequelae among people surviving TB; however, evidence from high-income, low-TB burden settings like Canada is lacking. In a person with TB infection, provision of TB preventive treatment (TPT) can prevent TB disease and its sequelae, but remains underused. We propose the Functional Outcomes, Lung health and Livelihood Outcomes among people With Tuberculosis study, a multicentre, prospective cohort study in Canada to help improve our understanding of the impacts of TPT and TB disease on individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a prospective cohort study taking place in Montreal and Vancouver, Canada. We aim to recruit and retain at least 120 people with microbiologically confirmed TB disease, 340 people treated for TB infection and 120 without TB disease or infection who will be considered our unexposed group. All participants must be \u22656 years of age. Participants with TB disease or infection will be recruited within 2 weeks of treatment initiation. We will follow-up unexposed participants and participants with TB disease for 24 months, and participants with TB infection for 12 months. Throughout follow-up, participants will complete assessments measuring lung health and function, quality of life, disability, dyspnoea, psychological distress, as well as changes in employment and direct and indirect costs incurred because of treatment. Among participants with TB disease, our primary outcome is the difference in quality-adjusted life years between participants with TB disease and those unexposed at 24 months. For participants with TB infection, our primary outcome is the identification of non-patient characteristics (eg, patient cost, quality of life) associated with participant decision to discontinue treatment. Patient partners have contributed to the design of the study and will be involved with the study through to its dissemination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has been approved by institutional ethics review boards at The Research Institute of the McGill University Health Centre (2025\u201310344) and The University of British Columbia (H24-02071). All participants will provide informed consent (and assent, if required) prior to participating in the study. We will disseminate study results to participants, national and international organisations, and through open-access peer-reviewed academic journals and conferences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-103256","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:46:54Z","timestamp":1762264014000},"page":"e103256","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Functional Outcomes, Lung health and Livelihood Outcomes among people With Tuberculosis (FOLLOW-TB): study protocol for a multicentre, prospective cohort study in Canada"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2341-2166","authenticated-orcid":false,"given":"Jonathon R.","family":"Campbell","sequence":"first","affiliation":[{"name":"Departments of Medicine and of Global and Public Health, McGill University, Montreal, Qu\u00e9bec, Canada"},{"name":"Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Qu\u00e9bec, Canada"},{"name":"McGill International TB Centre, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allita","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Flores","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Romanowski","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tenzin","family":"Kunor","sequence":"additional","affiliation":[{"name":"We are TB, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolelwa","family":"Sifumba","sequence":"additional","affiliation":[{"name":"Department of Public Health, Walter Sisulu University, Mthatha, Eastern Cape, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[{"name":"Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Qu\u00e9bec, Canada"},{"name":"McGill International TB Centre, McGill University, Montreal, Qu\u00e9bec, Canada"},{"name":"Departments of Medicine and of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-1159","authenticated-orcid":false,"given":"Kevin","family":"Schwartzman","sequence":"additional","affiliation":[{"name":"Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Qu\u00e9bec, Canada"},{"name":"McGill International TB Centre, McGill University, Montreal, Qu\u00e9bec, Canada"},{"name":"Department of Medicine, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zofia","family":"Zysman-Colman","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8314-9497","authenticated-orcid":false,"given":"Andrea","family":"Benedetti","sequence":"additional","affiliation":[{"name":"Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Qu\u00e9bec, Canada"},{"name":"McGill International TB Centre, McGill University, Montreal, Qu\u00e9bec, Canada"},{"name":"Departments of Medicine and of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Johnston","sequence":"additional","affiliation":[{"name":"McGill International TB Centre, McGill University, Montreal, Qu\u00e9bec, Canada"},{"name":"British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2025120413253674000_15.11.e103256.1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002152","article-title":"The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"key":"2025120413253674000_15.11.e103256.2","unstructured":"World Health Organization . Global Tuberculosis Report: 2024; Geneva, Switzerland, 2024. Available: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024 [accessed 06 Mar 2025]"},{"key":"2025120413253674000_15.11.e103256.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30919-1"},{"key":"2025120413253674000_15.11.e103256.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30309-3"},{"key":"2025120413253674000_15.11.e103256.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100752","article-title":"Post-tuberculosis airway disease: A population-based cohort study of people immigrating to British Columbia, Canada, 1985-2015","volume":"33","author":"Basham","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025120413253674000_15.11.e103256.6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.annepidem.2021.06.002","article-title":"Tuberculosis-associated depression: a population-based cohort study of people immigrating to British Columbia, Canada, 1985-2015","volume":"63","author":"Basham","year":"2021","journal-title":"Ann Epidemiol"},{"key":"2025120413253674000_15.11.e103256.7","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0279-6"},{"key":"2025120413253674000_15.11.e103256.8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/cid\/ciad290","article-title":"Healthcare Utilization After Respiratory Tuberculosis: A Controlled Interrupted Time Series Analysis","volume":"77","author":"Romanowski","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120413253674000_15.11.e103256.9","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-014-0858-6"},{"key":"2025120413253674000_15.11.e103256.10","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3201\/eid2809.220092","article-title":"Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010\u20132016","volume":"28","author":"Campbell","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2025120413253674000_15.11.e103256.11","unstructured":"World Health Organization . WHO End TB Strategy; Geneva, 2014."},{"key":"2025120413253674000_15.11.e103256.12","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.230228"},{"key":"2025120413253674000_15.11.e103256.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m549","article-title":"Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"2025120413253674000_15.11.e103256.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714283"},{"key":"2025120413253674000_15.11.e103256.15","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada","volume":"12","author":"Hirsch-Moverman","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025120413253674000_15.11.e103256.16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/cid\/ciad164","article-title":"Factors Associated With Discontinuation of Tuberculosis Preventive Treatment: Post Hoc Analysis of 2 Randomized, Controlled Trials","volume":"77","author":"Allard-Gray","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120413253674000_15.11.e103256.17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(19)30575-4","article-title":"Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials","volume":"20","author":"Campbell","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2025120413253674000_15.11.e103256.18","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(23)00096-6","article-title":"Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis","volume":"11","author":"Winters","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025120413253674000_15.11.e103256.19","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/cid\/ciad083","article-title":"Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection","volume":"76","author":"Sadowski","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120413253674000_15.11.e103256.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-019-1228-4","article-title":"Quality of life of patients on treatment for latent tuberculosis infection: a mixed-method study in Stockholm, Sweden","volume":"17","author":"Shedrawy","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"2025120413253674000_15.11.e103256.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-024-20868-0","article-title":"A systematic review exploring the role of tuberculosis stigma on test and treatment uptake for tuberculosis infection","volume":"25","author":"K\u0131l\u0131\u00e7","year":"2025","journal-title":"BMC Public Health"},{"key":"2025120413253674000_15.11.e103256.22","unstructured":"Public Health Agency of Canada . Tuberculosis disease in canada, 2023 (infographic). Ottawa (ON) Government of Canada; 2025. Available: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/tuberculosis-disease-2023-infographic.html [accessed 06 Mar 2025]"},{"key":"2025120413253674000_15.11.e103256.23","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/cid\/civ581","article-title":"Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update","volume":"61Suppl 3","author":"Graham","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025120413253674000_15.11.e103256.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-018-0777-3","article-title":"TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB - a study protocol","volume":"19","author":"Rachow","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2025120413253674000_15.11.e103256.25","unstructured":"American Thoracic Society . St. George\u2019s respiratory questionnaire (SGRQ). 2022. Available: https:\/\/www.thoracic.org\/members\/assemblies\/assemblies\/srn\/questionaires\/sgrq.php [Accessed 27 Sep 2022]."},{"key":"2025120413253674000_15.11.e103256.26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00070311"},{"key":"2025120413253674000_15.11.e103256.27","unstructured":"ePROVIDE . MMRC dyspnea scale. 2022. Available: https:\/\/eprovide.mapi-trust.org\/instruments\/modified-medical-research-council-dyspnea-scale [Accessed 27 Sep 2022]."},{"key":"2025120413253674000_15.11.e103256.28","unstructured":"EuroQol . Helping the world make better health decisions. Available: https:\/\/euroqol.org\/ [Accessed 25 Apr 2024]."},{"key":"2025120413253674000_15.11.e103256.29","unstructured":"Department of Health., Australia . Australia. kessler 10 (K10) assessment form. 2022. Available: https:\/\/www.healthtranslations.vic.gov.au\/site-14468\/resources\/kessler-10-k10-assessment-form [Accessed 27 Sep 2022]."},{"key":"2025120413253674000_15.11.e103256.30","doi-asserted-by":"crossref","unstructured":"Shahid A , Wilkinson K , Marcu S , et al . Center for epidemiological studies depression scale for children (CES-DC). In: Shahid A , Wilkinson K , Marcu S , et al , eds. STOP, THAT and One Hundred Other Sleep Scales. New York, NY: Springer, 2011: 93\u20136.","DOI":"10.1007\/978-1-4419-9893-4_16"},{"key":"2025120413253674000_15.11.e103256.31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11 Suppl 3","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"2025120413253674000_15.11.e103256.32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235821","article-title":"Cardiovascular morbidity and mortality among persons diagnosed with tuberculosis: A systematic review and meta-analysis","volume":"15","author":"Basham","year":"2020","journal-title":"PLoS ONE"},{"key":"2025120413253674000_15.11.e103256.33","unstructured":"REDCap. 2022. Available: https:\/\/projectredcap.org\/about\/ [Accessed 27 Sep 2022]."},{"key":"2025120413253674000_15.11.e103256.34","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000447"},{"key":"2025120413253674000_15.11.e103256.35","unstructured":"EuroQoL Group . EQ-5d-y-5l. euroqol. 2025. Available: https:\/\/euroqol.org\/information-and-support\/euroqol-instruments\/eq-5d-y-5l\/ [Accessed 06 Sep 2025]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-103256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:26:15Z","timestamp":1764883575000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-103256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2025-103256"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-103256","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}